logo
Plus   Neg
Share
Email

Moderna Regains Rights To Respiratory Syncytial Virus Vaccine From Merck - Quick Facts

Moderna, Inc., (MRNA) said it has regained all rights to the respiratory syncytial virus vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. Merck will complete the phase 1 study and transition the program to Moderna.

Moderna also announced the initiation of dosing in the phase 1 study of its solely owned RSV vaccine candidate (mRNA-1345). This phase 1 study includes initial dosing in adults, followed by age de-escalation into children.

Moderna and Merck will continue their ongoing collaboration in cancer vaccines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT